The Dysferlin Transcript Containing the Alternative Exon 40a is Essential for Myocyte Functions.

calpain (CAPN) dysferlin dysferlinopathies membrane neuromuscular disease

Journal

Frontiers in cell and developmental biology
ISSN: 2296-634X
Titre abrégé: Front Cell Dev Biol
Pays: Switzerland
ID NLM: 101630250

Informations de publication

Date de publication:
2021
Historique:
received: 27 08 2021
accepted: 04 11 2021
entrez: 10 12 2021
pubmed: 11 12 2021
medline: 11 12 2021
Statut: epublish

Résumé

Dysferlinopathies are a group of muscular dystrophies caused by recessive mutations in the DYSF gene encoding the dysferlin protein. Dysferlin is a transmembrane protein involved in several muscle functions like T-tubule maintenance and membrane repair. In 2009, a study showed the existence of fourteen dysferlin transcripts generated from alternative splicing. We were interested in dysferlin transcripts containing the exon 40a, and among them the transcript 11 which contains all the canonical exons and exon 40a. This alternative exon encodes a protein region that is cleaved by calpains during the muscle membrane repair mechanism. Firstly, we tested the impact of mutations in exon 40a on its cleavability by calpains. We showed that the peptide encoded by the exon 40a domain is resistant to mutations and that calpains cleaved dysferlin in the first part of DYSF exon 40a. To further explore the implication of this transcript in cell functions, we performed membrane repair, osmotic shock, and transferrin assay. Our results indicated that dysferlin transcript 11 is a key factor in the membrane repair process. Moreover, dysferlin transcript 11 participates in other cell functions such as membrane protection and vesicle trafficking. These results support the need to restore the dysferlin transcript containing the alternative exon 40a in patients affected with dysferlinopathy.

Identifiants

pubmed: 34888307
doi: 10.3389/fcell.2021.754555
pii: 754555
pmc: PMC8650162
doi:

Types de publication

Journal Article

Langues

eng

Pagination

754555

Informations de copyright

Copyright © 2021 Ballouhey, Courrier, Kergourlay, Gorokhova, Cerino, Krahn, Lévy and Bartoli.

Déclaration de conflit d'intérêts

OB, SC, and MB have filled a patent for dysferlin exon 40a inclusion in gene transfer. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Biochim Biophys Acta. 2009 Dec;1793(12):1886-93
pubmed: 19781581
Cell Death Dis. 2014 Jun 26;5:e1306
pubmed: 24967968
J Biol Chem. 2003 Dec 12;278(50):50466-73
pubmed: 14506282
Hum Mol Genet. 2014 Apr 1;23(7):1677-86
pubmed: 24203699
Hum Mol Genet. 2010 May 15;19(10):1897-907
pubmed: 20154340
Traffic. 2007 Jul;8(7):785-94
pubmed: 17547707
Curr Opin Cell Biol. 2007 Aug;19(4):409-16
pubmed: 17662592
FASEB J. 2014 Aug;28(8):3660-70
pubmed: 24784578
J Neurosci. 2013 Mar 20;33(12):5085-94
pubmed: 23516275
Nat Genet. 1998 Sep;20(1):37-42
pubmed: 9731527
Mol Biol Cell. 2014 Oct 1;25(19):3037-48
pubmed: 25143396
Proc Natl Acad Sci U S A. 2013 Dec 17;110(51):20831-6
pubmed: 24302765
Genet Test Mol Biomarkers. 2010 Feb;14(1):153-4
pubmed: 19929428
Sci Transl Med. 2010 Sep 22;2(50):50ra69
pubmed: 20861509
J Neuropathol Exp Neurol. 2011 Apr;70(4):302-13
pubmed: 21412170
FASEB J. 2014 Jul;28(7):2955-69
pubmed: 24687993
Traffic. 2012 Feb;13(2):185-94
pubmed: 21838746
Cell Signal. 2017 May;33:30-40
pubmed: 28192161
Mol Cell Proteomics. 2016 Apr;15(4):1262-80
pubmed: 26796116
Hum Gene Ther. 2018 Jul;29(7):749-762
pubmed: 28707952
Skelet Muscle. 2013 Feb 15;3(1):3
pubmed: 23414517
J Biol Chem. 2006 Jun 23;281(25):17092-17098
pubmed: 16608842
Ann Clin Transl Neurol. 2015 Mar;2(3):256-70
pubmed: 25815352
Nature. 2003 May 8;423(6936):168-72
pubmed: 12736685
Nat Biotechnol. 2004 Dec;22(12):1567-72
pubmed: 15558047
Hum Mol Genet. 2011 Feb 15;20(4):779-89
pubmed: 21127009
Hum Genet. 2009 May;125(4):413-20
pubmed: 19221801
Nat Genet. 1998 Sep;20(1):31-6
pubmed: 9731526
J Biol Chem. 2005 Dec 9;280(49):40632-41
pubmed: 16216885
Hum Mol Genet. 2001 Aug 15;10(17):1761-6
pubmed: 11532985

Auteurs

Océane Ballouhey (O)

INSERM, MMG, U1251, Aix Marseille University, Marseille, France.

Sébastien Courrier (S)

INSERM, MMG, U1251, Aix Marseille University, Marseille, France.

Virginie Kergourlay (V)

INSERM, MMG, U1251, Aix Marseille University, Marseille, France.

Svetlana Gorokhova (S)

INSERM, MMG, U1251, Aix Marseille University, Marseille, France.
AP-HM, Département de Génétique Médicale, Hôpital d'Enfants de la Timone, Marseille, France.

Mathieu Cerino (M)

INSERM, MMG, U1251, Aix Marseille University, Marseille, France.
AP-HM, Département de Génétique Médicale, Hôpital d'Enfants de la Timone, Marseille, France.

Martin Krahn (M)

INSERM, MMG, U1251, Aix Marseille University, Marseille, France.
AP-HM, Département de Génétique Médicale, Hôpital d'Enfants de la Timone, Marseille, France.

Nicolas Lévy (N)

INSERM, MMG, U1251, Aix Marseille University, Marseille, France.
AP-HM, Département de Génétique Médicale, Hôpital d'Enfants de la Timone, Marseille, France.
GIPTIS, Genetics Institute for Patients Therapies Innovation and Science, Marseille, France.

Marc Bartoli (M)

INSERM, MMG, U1251, Aix Marseille University, Marseille, France.

Classifications MeSH